Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DICERNA PHARMACEUTICALS, INC.

(DRNA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Nasdaq
11/26/2021 11/29/2021 11/30/2021 12/01/2021 Date
37.99(c) 38.08(c) 38.01(c) 38.1(c) 38.12 Last
11 096 778 10 487 528 5 430 792 3 476 406 3 193 027 Volume
-0.03% +0.24% -0.18% +0.24% +0.05% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 193 M - -
Net income 2021 -127 M - -
Net cash position 2021 544 M - -
P/E ratio 2021 -23,4x
Yield 2021 -
Sales 2022 191 M - -
Net income 2022 -149 M - -
Net cash position 2022 388 M - -
P/E ratio 2022 -21,5x
Yield 2022 -
Capitalization 2 977 M 2 977 M -
EV / Sales 2021 12,6x
EV / Sales 2022 13,5x
Nbr of Employees 302
Free-Float 92,8%
More Financials
Company
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. The Company's GalXC RNAi technology Platform consists of its liver-targeted GalXC technology and GalXC-Plus technology for tissues outside the... 
More about the company
Ratings of Dicerna Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about DICERNA PHARMACEUTICALS, INC.
11/22INSIDER SELL : Dicerna Pharmaceuticals
MT
11/22SHAREHOLDER ALERT : Monteverde & Associates PC Announces an Investigation of Dicerna Pharm..
PR
11/22Stifel Downgrades Dicerna Pharmaceuticals to Hold From Buy, Adjusts Price Target to $38..
MT
11/22Alnylam Pharmaceuticals Upgraded to Outperform From Sector Perform by RBC After R&D Day..
MT
11/22NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
11/19B. Riley Downgrades Dicerna Pharmaceuticals to Neutral from Buy After Announcing $3.3 B..
MT
11/19RBC Downgrades Dicerna Pharmaceuticals to Sector Perform From Outperform, Lifts PT to $..
MT
11/18SHAREHOLDER ALERT : WeissLaw LLP Investigates Dicerna Pharmaceuticals, Inc.
PR
11/18HC Wainwright Downgrades Dicerna Pharmaceuticals to Neutral From Buy, Adjusts PT to $38..
MT
11/18Health Care Stocks Ending Little Changed in Quiet Trading
MT
11/18Health Care Stocks Weakening This Afternoon
MT
11/18Dicerna Shares Soar on Takeover by Novo Nordisk
DJ
11/18SHAREHOLDER ALERT : Ademi LLP investigates whether Dicerna Pharmaceuticals, Inc. has obtai..
PR
11/18DICERNA MERGER INVESTIGATION : Halper Sadeh LLP Announces Investigation Into Whether the S..
BU
11/18Wall Street Set for Positive Open as Upbeat Nvidia Earnings Buoy Sentiment
MT
More news
News in other languages on DICERNA PHARMACEUTICALS, INC.
11/18Les actions du secteur de la santé terminent peu modifiées dans un marché calme
11/18Les actions du secteur de la santé s'affaiblissent cet après-midi
11/18DPA-AFX-ÜBERBLICK : UNTERNEHMEN vom 18.11.2021 - 15.15 Uhr
11/18Les actions du secteur de la santé en hausse jeudi avant le marché
11/18Novo Nordisk übernimmt Biotechnologie-Unternehmen Dicerna Pharmaceuticals
More news
Analyst Recommendations on DICERNA PHARMACEUTICALS, INC.
More recommendations
Chart DICERNA PHARMACEUTICALS, INC.
Duration : Period :
Dicerna Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DICERNA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Last Close Price 38,10 $
Average target price 34,96 $
Spread / Average Target -8,23%
EPS Revisions
Managers and Directors
Douglas M. Fambrough President, Chief Executive Officer & Director
Douglas W. Pagßn Chief Financial Officer
J. Kevin Buchi Chairman
Bob D. Brown Chief Scientific Officer
Shreeram Aradhye Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
DICERNA PHARMACEUTICALS, INC.72.95%2 977
GILEAD SCIENCES, INC.18.31%86 465
BIONTECH SE310.30%80 784
WUXI APPTEC CO., LTD.26.13%67 780
REGENERON PHARMACEUTICALS31.76%65 932
VERTEX PHARMACEUTICALS-13.26%52 122